Head-to-head · free

Stryker Corporation vs Teva Pharmaceutical Industries Limited

SYK vs TEVA — return on capital, cash generation, margins and balance sheet side by side.

SYK

4 / 7

measures where SYK leads

TEVA

3 / 7

measures where TEVA leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureSYK · FY2025TEVA · FY2025
Revenue$5.9B$1.5B
Net income$654.0M$1.4B
Revenue growth (yearly, multi-year)10.4%-44.6%
Free cash flow$4.3B—
Free cash flow margin73.0%—
Net cash / (debt)——
ROIC9.6%—
Return on equity15.1%21.2%
Gross margin64.0%51.8%
Operating margin20.1%22.9%
Net debt / EBITDA1.95x4.19x

Figures are as reported by each company; latest fiscal year shown.

Where Stryker Corporation's cash went (FY2025)

Capital spending
$761.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full SYK profile →

Where Teva Pharmaceutical Industries Limited's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TEVA profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons